ClinicalTrials.gg
CompletedNCT01815736Updated Apr 13, 2021Results posted

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

A Phase 3 interventional study of E/C/F/TAF and E/C/F/TDF in HIV and HIV Infections, sponsored by Gilead Sciences. Completed at 167 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-13.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,443
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing elvitegravir in HIV Infections — none open to participants now, none under way, none of them phase 3. elvitegravir · HIV Infections.

Enrollment
Largest of 11
1,443 · median 252
Started
2013
with 6 others
Phase 3
7 of 11
none open now
Registered
6th of 11
by date
Lead sponsor
11 of 11
Gilead Sciences

Among the 11 studies testing elvitegravir in HIV Infections, this one has the largest enrollment, is one of 7 that started in 2013, is one of 7 in phase 3, and was the 6th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 11 studies testing elvitegravir in HIV Infections is open now. The open studies under HIV Infections, anywhere →

About elvitegravir

elvitegravir: first FDA approval 2012 (STRIBILD), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing elvitegravir in HIV Infections as a file.
02

Study summary

The primary objective of this study is to evaluate the non-inferiority of switching to a tenofovir alafenamide (TAF)-containing fixed dose combination (FDC) relative to maintaining tenofovir disoproxil fumarate (TDF)-containing combination regimens in virologically suppressed HIV-infected participants as determined by having HIV-1 RNA \< 50 copies/mL at Week 48.

03

Conditions studied

  • HIV
  • HIV Infections

Browse trials for

Keywords

  • HIV
  • HIV 1 Infected
  • Virologically-Suppressed
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Ability to understand and sign a written form, which must be obtained prior to initiation of study procedures
  • Currently receiving antiretroviral therapy consisting of E/C/F/TDF, EFV/FTC/TDF, RTV+ATV+FTC/TDF, or COBI+ATV+FTC/TDF for ≥ 6 consecutive months preceding the final visit in their earlier study
  • Completion of the Week 144 visit in studies GS-US-236-0102, GS-US-236-0103, GS-US-216-0114, or completion of the Week 96 visit in study GS-US-264-0110 (only participants on an EFV-based regimen), or completion of studies GS-US-236-0104, GS-US-216-0105
  • Plasma type 1-ribonucleic acid (HIV-1 RNA) concentrations at undetectable levels for at least 6 consecutive months prior to the screening visit and have HIV RNA \< 50 copies/mL at the screening visit
  • Normal echocardiograph ()
  • Estimated (GFR) ≥ 50 mL/min according to the formula for creatinine clearance
  • Hepatic transaminases ( [AST] and alanine aminotransferase [ALT]) ≤ 5 × (ULN)
  • Direct ≤ 1.5 x ULN
  • Adequate hematologic function
  • Serum amylase ≤ 5 × ULN
  • Females of must agree to utilize highly effective methods or be non-heterosexually active or practice sexual abstinence from screening throughout the duration of study treatment and for 12 weeks following the last dose of study drug if receiving EFV/FTC/TDF regimen, and 30 days for those assigned to all other regimens.
  • Female participants who utilize hormonal contraceptive as one of their birth control methods must have used the same method for at least three months prior to study dosing
  • Female participants who have stopped menstruating for ≥ 12 months but do not have documentation of ovarian hormonal failure must have a serum follicle stimulating hormone (FSH) level at screening within the range based on the Central Laboratory reference range

Key Exclusion Criteria:

  • A new acquired immunodeficiency syndrome (AIDS)-defining condition diagnosed within the 30 days prior to screening
  • surface antigen position
  • antibody positive
  • Participants experiencing decompensated cirrhosis
  • Females who are breastfeeding
  • Positive serum pregnancy test
  • Have an implanted defibrillator or pacemaker
  • Current alcohol or substance use judged by the Investigator to potentially interfere with subject study compliance
  • History of within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, noninvasive cutaneous squamous carcinoma
  • Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to baseline
  • Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with dosing requirements
  • Participation in any other clinical trial without prior approval from the sponsor is prohibited while participating in this trial
  • Participants receiving ongoing therapy with drugs not to be used with elvitegravir (EVG), COBI, FTC, TDF, ATV, RTV, EFV, and TAF or participants with any known allergies to the of E/C/F/TDF, E/C/F/TAF, EFV/FTC/TDF, ATV, COBI, RTV, or FTC/TDF

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,443 participants (actual)

Study arms

  • Experimental
    E/C/F/TAF

    Randomized Phase: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) for up to 96 weeks. Extension Phase: After completing 96 weeks of randomized treatment, all participants will be given the opportunity to receive open-label E/C/F/TAF until it becomes commercially available, or until Gilead elects to terminate the development of E/C/F/TAF.

    Drug: E/C/F/TAF

  • Active comparator
    Stay on Baseline Treatment Regimen (SBR)

    Randomized Phase: Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted atazanavir (ATV)+FTC/TDF; or cobicistat (COBI-boosted ATV+FTC/TDF) administered according to prescribing information for up to 96 weeks. Extension Phase: After completing 96 weeks of randomized treatment (SBR), all participants will be given the opportunity to receive open-label E/C/F/TAF until it becomes commercially available, or until Gilead elects to terminate the development of E/C/F/TAF.

    Drug: E/C/F/TDF · Drug: EFV/FTC/TDF · Drug: RTV · Drug: ATV · Drug: FTC/TDF · Drug: COBI

Interventions

  • DrugE/C/F/TAF

    Drug pages: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide

    150/150/200/10 mg FDC tablet administered orally once daily

    Also known as: EVG/COBI/FTC/TAF; Genvoya®

  • DrugE/C/F/TDF

    150/150/200/300 mg FDC tablet administered orally once daily

    Also known as: Stribild®

  • DrugEFV/FTC/TDF

    600/200/300 mg FDC tablet administered orally once daily

    Also known as: Atripla®

  • DrugRTV

    100 mg tablet administered orally once daily

    Also known as: Norvir®

  • DrugATV

    300 mg capsule administered orally once daily

    Also known as: Reyataz®

  • DrugFTC/TDF

    200/300 mg tablet administered orally once daily

    Also known as: Truvada®

  • DrugCOBI

    150 mg tablet administered orally once daily

    Also known as: Tybost®, GS-9350

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

Secondary outcomes

  1. Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

    Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. BMD is calculated as grams per square centimeter (g/cm\^2); the mean (SD) percentage change is presented.

    Time frame: Baseline; Week 48

  2. Percent Change From Baseline in Spine BMD at Week 48

    Spine BMD was assessed by DXA scan. BMD is calculated as g/cm\^2; the mean (SD) percentage change is presented.

    Time frame: Baseline; Week 48

  3. Change From Baseline in Serum Creatinine at Week 48

    Time frame: Baseline; Week 48

  4. Change From Baseline in the Overall EFV-related Symptom Assessment Score at Week 48

    The mean (SD) change of the overall EFV-related symptom assessment score is presented. The overall symptom score (ranging from 0 to 20) is the sum of the individual symptom scores ranging from 0 (no symptoms) to 4 (most severe symptoms) from the 5 EFV-related symptom assessments (dizziness, trouble sleeping, impaired concentration, sleepiness, and abnormal or vivid dream). A negative change from baseline indicates improvement. EFV-Related Symptom Analysis Set: participants who received EFV/FTC/TDF as prior treatment, received at least 1 dose of study drug, and completed EFV-related symptom assessments at the baseline visit and at least 1 postbaseline visit.

    Time frame: Baseline; Week 48

  5. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 96

  6. Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 48

    The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

  7. Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 96

    The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 96

  8. Change From Baseline in Cluster Determinant 4 (CD4) Cell Count at Week 48

    The analysis of CD4 cell count included values up to 1 day after the last dose date of randomized study drug.The change from baseline in CD4 cell count for the full analysis set was based on observed data (ie, Missing = Excluded) for the total and by the prior treatment regimen.

    Time frame: Baseline; Week 48

  9. Change From Baseline in CD4 Cell Count at Weeks 96

    The analysis of CD4 cell count included values up to 1 day after the last dose date of randomized study drug.The change from baseline in CD4 cell count for the full analysis set was based on observed data (ie, Missing = Excluded) for the total and by the prior treatment regimen.

    Time frame: Baseline; Week 96

07

Results

Posted Apr 14, 2016
Limitations and caveats
There were no limitations affecting the analysis or results.

Participant flow

Participants were enrolled at study sites in Dominican Republic, Puerto Rico, North America, South America, Europe, Australia, and Asia. The first participant was screened on 27 March 2013. The last study visit occurred on 01 April 2020.

Randomized Treatment Phase-Up to Week 96
Participant flow — Randomized Treatment Phase-Up to Week 96
MilestoneE/C/F/TAFStay on Baseline Treatment Regimen (SBR)
Started963480
Completed914445
Not completed4935
Withdrew: Withdrew consent1117
Withdrew: Lost to follow-up109
Withdrew: Investigator's discretion112
Withdrew: Adverse event74
Withdrew: Death40
Withdrew: Lack of efficacy10
Withdrew: Pregnancy10
Withdrew: Participants randomized and never treated43
Extension Treatment Phase- After Week 96
Participant flow — Extension Treatment Phase- After Week 96
MilestoneE/C/F/TAFStay on Baseline Treatment Regimen (SBR)
Started905424
Completed854398
Not completed5126
Withdrew: Investigator's discretion3115
Withdrew: Lost to follow-up139
Withdrew: Withdrew consent51
Withdrew: Adverse event11
Withdrew: Death10

Outcome measures

PrimaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48
percentage of participantsE/C/F/TAFStay on Baseline Treatment Regimen (SBR)
NDA Data Cut95.692.9
All Participants97.293.1
Statistical analysis
  • E/C/F/TAF vs Stay on Baseline Treatment Regimen (SBR) · Cochran-Mantel-Haenszel · p = 0.051 (The p-value for the superiority test used a 2-sided Cochran-Mantel-Haenszel (CMH) test, stratified by prior treatment regimen.) · Difference in percentages: 2.7 · 95.01% CI -0.3 to 5.6The difference in percentages and its 95.01% confidence interval (CI) were calculated based on the Mantel-Haenszel (MH) proportion adjusted by the prior treatment regimen.
  • E/C/F/TAF vs Stay on Baseline Treatment Regimen (SBR) · Cochran-Mantel-Haenszel · p = <0.001 (The p-value for the superiority test used a 2-sided Cochran-Mantel-Haenszel (CMH) test, stratified by prior treatment regimen.) · Difference in percentages: 4.1 · 95% CI 1.6 to 6.7The difference in percentages and its 95% confidence interval (CI) were calculated based on the Mantel-Haenszel (MH) proportion adjusted by the prior treatment regimen.
SecondaryPercent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. BMD is calculated as grams per square centimeter (g/cm\^2); the mean (SD) percentage change is presented.

Time frame:
Baseline; Week 48
Reported as:
Mean · percentage change
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48
percentage changeE/C/F/TAFStay on Baseline Treatment Regimen (SBR)
NDA Data Cut1.949 ± 2.9956-0.136 ± 2.9890
All Participants1.468 ± 2.7136-0.340 ± 2.8280
Statistical analysis
  • E/C/F/TAF vs Stay on Baseline Treatment Regimen (SBR) · ANOVA · p = <0.001 (P-value was from the analysis of variance (ANOVA) model including study treatment and prior treatment regimen as fixed effects.) · Difference in least square means: 2.078 · 95% CI 1.697 to 2.459Difference in least squares means (LSM) and its 95% CI were from the ANOVA model including treatment and prior treatment regimen as fixed effects.
  • E/C/F/TAF vs Stay on Baseline Treatment Regimen (SBR) · ANOVA · p = <0.001 (P-value was from the analysis of variance (ANOVA) model including study treatment and prior treatment regimen as fixed effects.) · Difference in least square means: 1.807 · 95% CI 1.488 to 2.126Difference in least squares means and its 95% CI were from the ANOVA model including treatment and prior treatment regimen as fixed effects.
SecondaryPercent Change From Baseline in Spine BMD at Week 48

Spine BMD was assessed by DXA scan. BMD is calculated as g/cm\^2; the mean (SD) percentage change is presented.

Time frame:
Baseline; Week 48
Reported as:
Mean · percentage change
Percent Change From Baseline in Spine BMD at Week 48
percentage changeE/C/F/TAFStay on Baseline Treatment Regimen (SBR)
NDA Data Cut1.861 ± 3.0889-0.110 ± 3.7415
All Participants1.557 ± 3.8441-0.443 ± 4.1387
Statistical analysis
  • E/C/F/TAF vs Stay on Baseline Treatment Regimen (SBR) · ANOVA · p = <0.001 (P-value was from the analysis of variance (ANOVA) model including study treatment and prior treatment regimen as fixed effects.) · Difference in least square means: 1.970 · 95% CI 1.551 to 2.390Difference in least squares means (LSM) and its 95% CI were from the ANOVA model including treatment and prior treatment regimen as fixed effects.
  • E/C/F/TAF vs Stay on Baseline Treatment Regimen (SBR) · ANOVA · p = <0.001 (P-value was from the analysis of variance (ANOVA) model including study treatment and prior treatment regimen as fixed effects.) · Difference in least square means: 2.000 · 95% CI 1.549 to 2.452Difference in least squares means (LSM) and its 95% CI were from the ANOVA model including treatment and prior treatment regimen as fixed effects.
SecondaryChange From Baseline in Serum Creatinine at Week 48
Time frame:
Baseline; Week 48
Reported as:
Mean · mg/dL
Change From Baseline in Serum Creatinine at Week 48
mg/dLE/C/F/TAFStay on Baseline Treatment Regimen (SBR)
NDA Data Cut-0.01 ± 0.1170.04 ± 0.123
All Participants0.00 ± 0.1150.03 ± 0.105
Statistical analysis
  • E/C/F/TAF vs Stay on Baseline Treatment Regimen (SBR) · ANCOVA · p = <0.001 (P-value was from analysis of covariance (ANCOVA) model including study treatment and prior treatment as fixed effects and baseline serum creatinine as a covariate.) · Difference in least square means: -0.05 · 95% CI -0.07 to -0.03Difference in least squares means (LSM) and its 95% CI were from the analysis of covariance (ANCOVA) model including study treatment and prior treatment regimen as fixed effects and baseline serum creatinine as a covariate.
  • E/C/F/TAF vs Stay on Baseline Treatment Regimen (SBR) · ANCOVA · p = <0.001 (P-value was from analysis of covariance (ANCOVA) model including study treatment and prior treatment as fixed effects and baseline serum creatinine as a covariate.) · Difference in least square means: -0.04 · 95% CI -0.05 to -0.02Difference in least squares means (LSM) and its 95% CI were from the analysis of covariance (ANCOVA) model including study treatment and prior treatment regimen as fixed effects and baseline serum creatinine as a covariate.
SecondaryChange From Baseline in the Overall EFV-related Symptom Assessment Score at Week 48

The mean (SD) change of the overall EFV-related symptom assessment score is presented. The overall symptom score (ranging from 0 to 20) is the sum of the individual symptom scores ranging from 0 (no symptoms) to 4 (most severe symptoms) from the 5 EFV-related symptom assessments (dizziness, trouble sleeping, impaired concentration, sleepiness, and abnormal or vivid dream). A negative change from baseline indicates improvement. EFV-Related Symptom Analysis Set: participants who received EFV/FTC/TDF as prior treatment, received at least 1 dose of study drug, and completed EFV-related symptom assessments at the baseline visit and at least 1 postbaseline visit.

Time frame:
Baseline; Week 48
Reported as:
Mean · units on a scale
Change From Baseline in the Overall EFV-related Symptom Assessment Score at Week 48
units on a scaleE/C/F/TAFStay on Baseline Treatment Regimen (SBR)
NDA Data Cut-1.6 ± 3.06-0.1 ± 2.43
All Participants-1.5 ± 3.06-0.1 ± 2.39
Statistical analysis
  • E/C/F/TAF vs Stay on Baseline Treatment Regimen (SBR) · Wilcoxon (Mann-Whitney) · p = <0.001 (The P-value comparing the 2 treatment groups was from the 2-sided Wilcoxon rank sum test.)
  • E/C/F/TAF vs Stay on Baseline Treatment Regimen (SBR) · Wilcoxon (Mann-Whitney) · p = <0.001 (The P-value comparing the 2 treatment groups was from the 2-sided Wilcoxon rank sum test.)
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96
percentage of participantsE/C/F/TAFStay on Baseline Treatment Regimen (SBR)
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 9692.889.1
Statistical analysis
  • E/C/F/TAF vs Stay on Baseline Treatment Regimen (SBR) · Cochran-Mantel-Haenszel · p = 0.017 (P-value for the superiority test comparing the percentages of virologic success was from the CMH test stratified by the prior treatment regimen (STB, ATR, ATV/boosted+TVD).) · Difference in percentages: 3.7 · 95% CI 0.4 to 7.0The difference in percentages of virologic success and its 95% CI were calculated based on the MH proportion adjusted by the prior treatment regimen.
SecondaryPercentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 48

The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 48
percentage of participantsE/C/F/TAFStay on Baseline Treatment Regimen (SBR)
NDA Data Cut92.290.4
All Participants93.590.4
Statistical analysis
  • E/C/F/TAF vs Stay on Baseline Treatment Regimen (SBR) · Cochran-Mantel-Haenszel · p = 0.29 (P-value for the superiority test comparing the percentages of virologic success was from the CMH test stratified by the prior treatment regimen (STB, ATR, ATV/boosted+TVD).) · Difference in percentages: 1.8 · 95% CI -1.7 to 5.3Difference in percentages of virologic success and its 95% CI were calculated based on the MH proportion adjusted by the prior treatment regimen.
  • E/C/F/TAF vs Stay on Baseline Treatment Regimen (SBR) · Cochran-Mantel-Haenszel · p = 0.031 (P-value for the superiority test comparing the percentages of virologic success was from the CMH test stratified by the prior treatment regimen (STB, ATR, ATV/boosted+TVD).) · Difference in percentages: 3.2 · 95% CI 0.1 to 6.3Difference in percentages of virologic success and its 95% CI were calculated based on the MH proportion adjusted by the prior treatment regimen.
SecondaryPercentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 96

The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 96
percentage of participantsE/C/F/TAFStay on Baseline Treatment Regimen (SBR)
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 9690.685.3
Statistical analysis
  • E/C/F/TAF vs Stay on Baseline Treatment Regimen (SBR) · Cochran-Mantel-Haenszel · p = 0.003 (P-value for the superiority test comparing the percentages of virologic success was from the CMH test stratified by the prior treatment regimen (STB, ATR, ATV/boosted+TVD).) · Difference in percentages: 5.3 · 95% CI 1.6 to 9.0Difference in percentages of virologic success and its 95% CI were calculated based on the MH proportion adjusted by the prior treatment regimen.
SecondaryChange From Baseline in Cluster Determinant 4 (CD4) Cell Count at Week 48

The analysis of CD4 cell count included values up to 1 day after the last dose date of randomized study drug.The change from baseline in CD4 cell count for the full analysis set was based on observed data (ie, Missing = Excluded) for the total and by the prior treatment regimen.

Time frame:
Baseline; Week 48
Reported as:
Mean · cells/uL
Change From Baseline in Cluster Determinant 4 (CD4) Cell Count at Week 48
cells/uLE/C/F/TAFStay on Baseline Treatment Regimen (SBR)
Baseline (NDA Data Cut)712 ± 267.9690 ± 251.4
Change at Week 48 (NDA Data Cut)33 ± 166.627 ± 160.2
Baseline (All Participants)701 ± 261.8689 ± 248.0
Change at Week 48 (All Participants)35 ± 164.624 ± 156.1
Statistical analysis
  • E/C/F/TAF vs Stay on Baseline Treatment Regimen (SBR) · ANOVA · p = 0.56 (P-values were from the analysis of variance (ANOVA) model including treatment (E/C/F/TAF vs. SBR) and prior treatment regimen (STB, ATR, ATV/boosted+TVD) as fixed effects.) · Difference in least squares means: 6 · 95% CI -14 to 26Difference in least squares means (Diff in LSM), and its 95% CI were from the analysis of variance (ANOVA) model including treatment (E/C/F/TAF vs. FTC/TDF+3rd Agent) and prior treatment regimen (STB, ATR, ATV/boosted+TVD) as fixed effects.
  • E/C/F/TAF vs Stay on Baseline Treatment Regimen (SBR) · ANOVA · p = 0.26 (P-values were from the analysis of variance (ANOVA) model including treatment (E/C/F/TAF vs. SBR) and prior treatment regimen (STB, ATR, ATV/boosted+TVD) as fixed effects.) · Difference in least squares means: 11 · 95% CI -8 to 29Difference in least squares means and its 95% CI were from the analysis of variance (ANOVA) model including treatment (E/C/F/TAF vs.SBR) and prior treatment regimen (STB, ATR, ATV/boosted+TVD) as fixed effects.
SecondaryChange From Baseline in CD4 Cell Count at Weeks 96

The analysis of CD4 cell count included values up to 1 day after the last dose date of randomized study drug.The change from baseline in CD4 cell count for the full analysis set was based on observed data (ie, Missing = Excluded) for the total and by the prior treatment regimen.

Time frame:
Baseline; Week 96
Reported as:
Mean · cells/uL
Change From Baseline in CD4 Cell Count at Weeks 96
cells/uLE/C/F/TAFStay on Baseline Treatment Regimen (SBR)
Baseline701 ± 261.8689 ± 248.0
Change at Week 9660 ± 181.642 ± 158.0
Statistical analysis
  • E/C/F/TAF vs Stay on Baseline Treatment Regimen (SBR) · ANOVA · p = 0.074 (P-values were from the analysis of variance (ANOVA) model including treatment (E/C/F/TAF vs. SBR) and prior treatment regimen (STB, ATR, ATV/boosted+TVD) as fixed effects.) · Difference in least squares means: 18 · 95% CI -2 to 38Difference in least squares means and its 95% CI were from the analysis of variance (ANOVA) model including treatment (E/C/F/TAF vs. SBR) and prior treatment regimen (STB, ATR, ATV/boosted+TVD) as fixed effects.

Adverse events

Collected over From the first dose date up to last dose date ( maximum: 307.7 weeks) plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Randomized Phase: E/C/F/TAF4/963 (0.4%)79/959 (8.2%)620/959 (64.7%)
Randomized Phase: Stay on Baseline Treatment Regimen (SBR)0/480 (0%)39/477 (8.2%)286/477 (60%)
Extension Phase: E/C/F/TAF From E/C/F/TAF1/905 (0.1%)27/905 (3%)298/905 (32.9%)
Extension Phase: E/C/F/TAF From SBR1/424 (0.2%)22/424 (5.2%)144/424 (34%)
Most frequent serious events
Showing 10 of 163
Most frequent serious events
EventRandomized Phase: E/C/F/TAFRandomized Phase: Stay on Baseline Treatment Regimen (SBR)Extension Phase: E/C/F/TAF From E/C/F/TAFExtension Phase: E/C/F/TAF From SBR
PneumoniaInfections and infestations5/9590/4770/9052/424
Abdominal painGastrointestinal disorders3/9590/4770/9052/424
DiarrhoeaGastrointestinal disorders1/9592/4771/9052/424
Chest painGeneral disorders1/9590/4770/9052/424
PyrexiaGeneral disorders0/9590/4770/9052/424
Myocardial infarctionCardiac disorders1/9592/4770/9050/424
CellulitisInfections and infestations0/9592/4772/9050/424
InfluenzaInfections and infestations0/9592/4770/9050/424
OsteomyelitisInfections and infestations1/9592/4770/9050/424
DepressionPsychiatric disorders0/9592/4770/9050/424
Most frequent other events
Showing 10 of 17
Most frequent other events
EventRandomized Phase: E/C/F/TAFRandomized Phase: Stay on Baseline Treatment Regimen (SBR)Extension Phase: E/C/F/TAF From E/C/F/TAFExtension Phase: E/C/F/TAF From SBR
Upper respiratory tract infectionInfections and infestations168/95964/47767/90526/424
DiarrhoeaGastrointestinal disorders109/95951/47740/90522/424
NasopharyngitisInfections and infestations96/95948/47747/90520/424
HeadacheNervous system disorders83/95925/47718/9059/424
ArthralgiaMusculoskeletal and connective tissue disorders78/95931/47719/9058/424
SyphilisInfections and infestations63/95938/47719/9059/424
CoughRespiratory, thoracic and mediastinal disorders73/95931/47728/90513/424
InsomniaPsychiatric disorders58/95936/47712/9058/424
Back painMusculoskeletal and connective tissue disorders70/95933/47730/9059/424
BronchitisInfections and infestations69/95926/47717/90513/424

Baseline characteristics

Safety Analysis Set included participants who were randomized and received at least one dose of study drug.

Age, Continuous
Age, Continuous(Years)E/C/F/TAFStay on Baseline Treatment Regimen (SBR)Total
Mean41 ± 10.141 ± 10.141 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)E/C/F/TAFStay on Baseline Treatment Regimen (SBR)Total
Female10350153
Male8564271283
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)E/C/F/TAFStay on Baseline Treatment Regimen (SBR)Total
Race — American Indian or Alaska Native527
Race — Asian593594
Race — Black169102271
Race — Native Hawaiian or Pacific Islander617
Race — White651314965
Race — Local regulators did not allow collection of race or ethnicity information213
Race — Other672289
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)E/C/F/TAFStay on Baseline Treatment Regimen (SBR)Total
Ethnicity — Hispanic or Latino24882330
Ethnicity — Not Hispanic or Latino7093921101
Ethnicity — Local regulators did not allow collection of race or ethnicity information235
Region of Enrollment
Region of Enrollment(participants)E/C/F/TAFStay on Baseline Treatment Regimen (SBR)Total
United States648316964
United Kingdom14822
Thailand352156
Portugal8210
Switzerland549
Spain538
Canada512778
Austria16824
Netherlands235
Sweden101
Belgium14822
Brazil14519
Denmark123
Dominican Republic291342
Italy13619
Mexico19625
Australia382260
France121224
Germany341145
HIV-1 RNA Category
HIV-1 RNA Category(Participants)E/C/F/TAFStay on Baseline Treatment Regimen (SBR)Total
< 50 copies/mL9434661409
≥ 50 copies/mL161127
08

Study locations

167 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Southwest Center for HIV/AIDS
    Phoenix, Arizona 85006, United States
  • Spectrum Medical Group
    Phoenix, Arizona 85012, United States
  • Health for Life Clinic PLLC
    Little Rock, Arkansas 72207, United States
  • AHF Research Center
    Beverly Hills, California 90211, United States
  • Michael Keith Wensley, MD, Inc., A Medical Corporation
    Costa Mesa, California 92626, United States
  • Living Hope Clinical Foundation
    Long Beach, California 90813, United States
  • Kaiser Permanente
    Los Angeles, California 90027, United States
  • Jeffrey Goodman Special Care Clinic
    Los Angeles, California 90028, United States
  • Peter J Ruane, MD, Inc
    Los Angeles, California 90036, United States
  • Anthony Mills MD Inc
    Los Angeles, California 90069, United States
  • Orange Coast Medical Group
    Newport Beach, California 92663, United States
  • Alameda County Medical Center
    Oakland, California 94602, United States
  • East Bay AIDS Center
    Oakland, California 94609, United States
  • Stanford University
    Palo Alto, California 94303, United States
  • University of California, Davis Medical Center
    Sacramento, California 95817, United States
  • Kaiser Permanente Medical Group
    Sacramento, California 95825, United States
  • La Playa Medical Group and Clinical Research
    San Diego, California 92103, United States
  • Metropolis Medical Group
    San Francisco, California 94109, United States
  • Kaiser Permanente Medical Center, Clinical Trials Unit
    San Francisco, California 94118, United States
  • Kaiser Permanente Hospital
    San Leandro, California 94577, United States
  • Apex Research LLC
    Denver, Colorado 80209, United States
  • Greenwich Hospital
    Greenwich, Connecticut 06830, United States
  • Yale University HIV Clinical Trials Program
    New Haven, Connecticut 06510, United States
  • Dupont Circle Physicians Group
    Washington, District of Columbia 20009, United States
  • Whitman Walker Clinic
    Washington, District of Columbia 20009, United States
  • Capital Medical Associates, PC
    Washington, District of Columbia 20036, United States
  • George Washington University Medical Faculty Associates
    Washington, District of Columbia 20037, United States
  • Therafirst Medical Center
    Fort Lauderdale, Florida 33308, United States
  • Broward Health/Comprehensive Care Center
    Fort Lauderdale, Florida 33311, United States
  • Gary J. Richmond,M.D.,P.A.
    Fort Lauderdale, Florida 33316, United States
  • Midway Immunology and Research Center
    Fort Pierce, Florida 34982, United States
  • Wohlfeiler, Piperato and Associates, LLC
    Miami Beach, Florida 33139, United States
  • The Kinder Medical Group
    Miami, Florida 33133, United States
  • Orlando Immunology Center
    Orlando, Florida 32803, United States
  • IDOCF/ Value Health MD, LLC
    Orlando, Florida 32806, United States
  • University of South Florida HIV Clinical Research Unit / Hillsborough County Health Department
    Tampa, Florida 33602, United States
  • Infectious Disease Research Institute Inc.
    Tampa, Florida 33614, United States
  • St. Joseph's Comprehensive Research Institute
    Tampa, Florida 33615, United States
  • AIDS Research Consortium of Atlanta
    Atlanta, Georgia 30308, United States
  • Atlanta ID Group, PC
    Atlanta, Georgia 30309, United States
  • Infectious Disease Specialists of Atlanta
    Decatur, Georgia 30033, United States
  • Mercer University School of Medicine
    Macon, Georgia 31201, United States
  • University of Hawaii - Hawaii Center for AIDS
    Honolulu, Hawaii 96816, United States
  • Ruth M. Rothstein CORE Center
    Chicago, Illinois 60612, United States
  • Howard Brown Health Center
    Chicago, Illinois 60613, United States
  • NorthStar Medical Center
    Chicago, Illinois 60657, United States
  • Community Research Initiative of New England
    Boston, Massachusetts 02111, United States
  • The Research Institute
    Springfield, Massachusetts 01105, United States
  • Baystate Infectious Diseases Clinical Research
    Springfield, Massachusetts 01199, United States
  • Be Well Medical Center
    Berkley, Michigan 48072, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Hennepin County Medical Center
    Minneapolis, Minnesota 55415, United States
  • Central West Clinical Research
    Saint Louis, Missouri 63108, United States
  • Saint Louis University
    Saint Louis, Missouri 63110, United States
  • Southampton Healthcare
    Saint Louis, Missouri 63139, United States
  • ID Care
    Hillsborough, New Jersey 08844, United States
  • Saint Michaels Medical Center
    Newark, New Jersey 07102, United States
  • South Jersey Infectious Disease
    Somers Point, New Jersey 08244, United States
  • SouthWest CARE Center
    Santa Fe, New Mexico 87505, United States
  • Upstate ID Association
    Albany, New York 12208, United States
  • Albany Medical College
    Albany, New York 12209, United States
  • Jacobi Medical Center
    Bronx, New York 10461, United States
  • Montefiore Medical Center - AIDS Center
    Bronx, New York 10467, United States
  • New York Hospital Queens
    Flushing, New York 11355, United States
  • North Shore University Hospital, Divison of Infectious Diseases
    Manhasset, New York 11030, United States
  • Greiger Clinic
    Mount Vernon, New York 10550, United States
  • Beth Israel Medical Center- Division of Infectious Diseases
    New York, New York 10003, United States
  • Chelsea Village Medical, PC
    New York, New York 10011, United States
  • Ricky K. Hsu, MD
    New York, New York 10011, United States
  • University of NC AIDS Clinical Trials Unit
    Chapel Hill, North Carolina 27599, United States
  • Carolinas Medical Center-Myers Park
    Charlotte, North Carolina 28207, United States
  • Duke University Health System
    Durham, North Carolina 27710, United States
  • East Carolina University
    Greenville, North Carolina 27834, United States
  • Rosedale Infectious Diseases
    Huntersville, North Carolina 28078, United States
  • Summa Health System
    Akron, Ohio 44304, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Palmetto Health Richland
    Columbia, South Carolina 29203, United States
  • AIDS Arms, Inc./ Peabody Health Center
    Dallas, Texas 75215, United States
  • Southwest Infectious Disease Clinical Research, Inc.
    Dallas, Texas 75219, United States
  • Tarrant County Infectious Disease Associates
    Fort Worth, Texas 76104, United States
  • Garcia's Family Health Group
    Harlingen, Texas 78550, United States
  • Therapeutic Concepts, P.A.
    Houston, Texas 77004, United States
  • Gordon E. Crofoot MD PA
    Houston, Texas 77098, United States
  • Research Access Network
    Houston, Texas 77098, United States
  • DCOL Center for Clinical Research
    Longview, Texas 75605, United States
  • Clinical Alliance for Research & Education, Infectious Diseases (CARE-ID)
    Annandale, Virginia 22003, United States
  • Peter Shalit, M.D.
    Seattle, Washington 98104, United States
  • Premier Clinical Research
    Spokane, Washington 99202, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • East Sydney Doctors
    Darlinghurst, New South Wales 2010, Australia
  • Holdsworth House Medical practice
    Darlinghurst, New South Wales 2010, Australia
  • St Vincent's Hospital, Sydney
    Darlinghurst, New South Wales 2010, Australia
  • Taylor Square Private Clinic
    Darlinghurst, New South Wales 2010, Australia
  • Albion Street Centre
    Surry Hills, New South Wales 2010, Australia
  • Melbourne Sexual Health Clinic
    Carlton, Victoria 3053, Australia
  • Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • Northside Clinic
    Melbourne, Victoria 3068, Australia
  • Prahran Market Clinic
    South Yarra, Victoria 3141, Australia

Showing the first 100 of 167 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Mills A, Arribas JR, Andrade-Villanueva J, DiPerri G, Van Lunzen J, Koenig E, Elion R, Cavassini M, Madruga JV, Brunetta J, Shamblaw D, DeJesus E, Orkin C, Wohl DA, Brar I, Stephens JL, Girard PM, Huhn G, Plummer A, Liu YP, Cheng AK, McCallister S; GS-US-292-0109 team. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016 Jan;16(1):43-52. doi: 10.1016/S1473-3099(15)00348-5. Epub 2015 Nov 2. PubMed 26538525 ↗
  • Orkin C, DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, Mills A, Vandercam B, de Wet J, Rockstroh J, Lazzarin A, Rijnders B, Podzamczer D, Thalme A, Stoeckle M, Porter D, Liu HC, Cheng A, Quirk E, SenGupta D, Cao H. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV. 2017 May;4(5):e195-e204. doi: 10.1016/S2352-3018(17)30031-0. Epub 2017 Mar 2. PubMed 28259777 ↗
  • Brown T, Yin MT, Gupta S, Katlama C, et al. Switching from TDF to TAF in HIV-infected adults with low BMD: a pooled analysis. 24th Annual Conference on Retroviruses and Opportunistic Infections (CROI) - CROI Foundation 2017; poster presentation: abstract #683.
  • Podzamczer D, Viciana P, Rijnders B, Shalit P, et al. Switching from Tenofovir disoproxil fumarate to tenofovir alafenamide in patients with high risk for chronic kidney disease. 8th National Congress of the AIDS Study Group (GESIDA) and Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) held jointly with the 9th Teacher Meeting of AIDS Research Network 2016; poster presentation: abstract #P-188.
  • Orkin C, Rjinders B, Stephan C, McKellar M, et al. Switching from boosted atazanavir (ATV) plus FTC/TDF to a TAF-based single tablet regimen (STR): Week 48 data in virologically suppressed adults. Annual Conference of the British Association for Sexual Health and HIV (BASHH) 2016; poster presentation: abstract # P045.
  • Mills A, Andrade J, Koenig E, et al. Switching from a tenofovir disoproxil fumarate (TDF)-based regimen to a tenofovir alafenamide (TAF)-based regimen: data in virologically suppressed adults through 48 weeks of treatment. 13th Congress for Infectious Diseases and Tropical Medicine (KIT) 2016; poster presentation: abstract #eP-038.
  • Overton ET, Shalit P, Crofoot G, Benson P, et al. Switch from TDF regimens to E/C/F/TAF is associated with improved bone mineral density (BMD), decreased serum PTH and decreased bone turnover biomarkers. 56th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held Jointly with the 2016 Annual Meeting on Microbe - American Society for Microbiology (ASM) 2016; poster presentation: abstract #PW-027.
  • Huhn G, Rijnders B, Thompson M, Tebas P, et al. Switching from TDF to TAF in patients with high risk for CKD. 56th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held Jointly with the 2016 Annual Meeting on Microbe - American Society for Microbiology (ASM) 2016; oral presentation: https://www.natap.org/2016/HIV/062116_01.htm.
  • Abram M, Margot NA, Cox S, Ram RR, et al. Pooled week-48 analysis of HIV-1 drug resistance in E/C/F/TAF (Genvoya) phase 3 studies. 23rd Annual Conference on Retroviruses and Opportunistic Infections (CROI) - CROI Foundation 2016, poster presentation: abstract #496.
  • Abram M, Margot NA, Cox S, Ram RR, et al. Pooled week-48 analysis of HIV-1 drug resistance in E/C/F/TAF (Genvoya) phase 3 studies. 25th International HIV Drug Resistance Workshop - Informed Horizons, LLC 2016; poster presentation: abstract #33.
  • Mills A, Andrade J, Di Perri G, Van Lunzen J, et al. Switching from a tenofovir disoproxil fumarate (TDF)-based regimen to a tenofovir alafenamide (TAF)-based regimen: data in virologically suppressed adults through 48 weeks of treatment. 8th Biennial Conference on HIV Pathogenesis and Treatment and Prevention of the International AIDS Society (IAS) 2015; oral presentation: abstract #TUAB0102.
  • Shamblaw D, Van Lunzen J, Orkin C, Bloch M, eta al. Switching from Atripla (ATR) to a tenofovir alafenamide (TAF)-based single tablet regimen: week 48 data in virologically suppressed adults. 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2015; oral presentation; https://natap.org/2015/ICAAC/ICAAC_13.htm.
  • Thompson M, Morales-Ramirez J, Mcdonald C, Rachlis A, et al. Switching from a tenofovir disoproxil fumarate (TDF) to a tenofovir alafenamide (TAF)-based single tablet regimen (STR): Week 48 data in HIV-1 infected virologically suppressed adults. Spring Conference of the Society for Healthcare Epidemiology of America (SHEA) 2015; oral presentation: abstract #725.
  • Rijnders B, Stephan C, Lazzarin A, Squires K, et al. Switching from ritonavir or cobicistat boosted atazanavir (ATV) plus emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) to a tenofovir alafenamide (TAF)-based single tablet regimen (STR): week 48 data in virologically suppressed adults. 15th European AIDS Conference (EACS) and 17th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV 2015; poster presentation: abstract #577.
  • Lutz T, Benson P, Goffard J-C, Haubrich R, et al. Patient reported outcomes (PRO) over 48 weeks in a randomized, open-label trial of patients with HIV switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF). 15th European AIDS Conference (EACS) and 17th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV 2015; poster presentation: abstract #324.
  • Viciana P, Mills A, Andrade J, Diperri G, et al. Switching from a tenofovir disoproxil fumarate (TDF)-based regimen to a tenofovir alafenamide (TAF)-based regimen: data in virologically suppressed adults through 48 weeks of treatment. 7th National Congress of the AIDS Study Group (GESIDA) and Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) held jointly with the 8th Teacher Meeting of AIDS Research Network 2015; oral presentation: abstract #PO-08.
  • Mills A, Andrade-Villanueva J, DiPerri G, Van Luzen J, et al. Switching from a tenofovir disoproxil fumarate (TDF)-based regimen to a tenofovir alafenamide (TAF)-based regimen: Data in virologically suppressed adults through 48 weeks of treatment. 8th Annual International AIDS Society meeting 2015; oral presentation: abstract #839.
  • Thompson M, Brar I, Brinson C, Creticos C, et al. Tenofovir alafenamide vs tenofovir DF in women: pooled analysis of 7 clinical trials. Annual Meeting of the American Pharmacists Association (APhA) - Virtual 2020; poster presentation: abstract #209.
  • Stellbrink H, Gandhi-Patel B, Zhong L, Das M, et al. Safety and efficacy of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV aged 50 years and older. Annual Meeting of the American Pharmacists Association (APhA) - Virtual 2020; poster presentation: abstract #205.
  • Stellbrink H-J, Post FA, Podzamczer D, Arribas J, et al. Safety and efficacy of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV aged 50 years and older. 15th Congress on Infectious Diseases and Tropical Medicine - German Society for Infectious Diseases (DPID) held jointly with the 29th Annual Meeting of the German Society for Pediatric Infectiology (DGPI) 2020; poster presentation: abstract #A-343.
  • Gupta SK, Post FA, Arribas JR, Eron JJ Jr, Wohl DA, Clarke AE, Sax PE, Stellbrink HJ, Esser S, Pozniak AL, Podzamczer D, Waters L, Orkin C, Rockstroh JK, Mudrikova T, Negredo E, Elion RA, Guo S, Zhong L, Carter C, Martin H, Brainard D, SenGupta D, Das M. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. AIDS. 2019 Jul 15;33(9):1455-1465. doi: 10.1097/QAD.0000000000002223. PubMed 30932951 ↗
  • Hermansson L, Yilmaz A, Price RW, Nilsson S, McCallister S, Makadzange T, Das M, Zetterberg H, Blennow K, Gisslen M. Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate. PLoS One. 2019 Dec 11;14(12):e0226276. doi: 10.1371/journal.pone.0226276. eCollection 2019. PubMed 31826005 ↗
  • Stellbrink H-J, Post FA, Podzamczer D, Arribas J, et al. Safety and efficacy of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV aged 50 years and older. 17th European AIDS Conference of the European AIDS Clinical Society (EACS) 2019; poster presentation: abstract #PE9-50.
  • Pepperrell T, Hughes S, Gotham D, Pozniak A, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate - is there a true difference in safety? 17th European AIDS Conference of the European AIDS Clinical Society (EACS) 2019; poster presentation: abstract #PE3-8.
  • Thompson M, Brar I, Brinson C, Creticos C, et al. Tenofovir alafenamide vs. tenofovir DF in women: pooled analysis of 7 clinical trials. 9th Edition International Workshop on HIV and Women - Virology Education 2019; poster presentation: abstract #21.
  • Dejesus E, Federico Andrade Villanueva J, Ramon Arribas Lopez J, Brinson C, et al. Tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in hispanic/latinx and black participants: efficacy, bone and renal safety results from a pooled analysis of 7 clinical trials. IDWeek Meeting of the Infectious Diseases Society of America (IDSA) 2019; poster presentation: abstract #318.
  • Walmsley S, Andany N, Brar I, Brinson C, et al. Tenofovir alafenamide VS tenofovir DF in women: pooled analysis of 7 clinical trials. 28th Annual Canadian Conference on HIV/AIDS Research - Canadian Association for HIV Research (CAHR) 2019; poster presentation: abstract #CSP9.04.
  • Kim YS, Oka S, Chetchotisakd P, Clarke A, Supparatpinyo K, Avihingsanon A, Ratanasuwan W, Kiertiburanakul S, Ruxrungtham K, Yang S, Guo S, Liu Y, Das M, Tran D, McColl D, Corales R, Nguyen C, Piontkowsky D. Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials. HIV Res Clin Pract. 2019 Jun;20(3):73-81. doi: 10.1080/15284336.2019.1589232. Epub 2019 Jul 8. PubMed 31303140 ↗
  • Hermansson L, Price RW, Yilmaz A, Nilsson S, et al. Effect on plasma NFL, a marker or neuronal injury, after switching from TDF to TAF. Annual Conference on Retroviruses and Opportunistic Infections (CROI) - CROI Foundation 2019; oral presentation: abstract #127.
  • Thompson M, Brar I, Brinson C, Creticos C, et al. Tenofovir alafenamide VS tenofovir DF in women: pooled analysis of 7 clinical trials. Annual Conference on Retroviruses and Opportunistic Infections (CROI) - CROI Foundation 2019; poster presentation: abstract #519.
  • Orkin C, Castelli F, Yazdanpanah Y, Rockstroh J, et al. Cardiovascular disease risk assessments and fasting lipid changes in virologically suppressed patients randomized to switch to tenofovir alafenamide versus continuing tenofovir disoproxil fumarate. 22nd International AIDS Conference - International AIDS Society 2018; poster presentation: abstract #TUPEB104.
  • Brown TT, Yin MT, Gupta SK, Short WR, et al. Combined effects of bisphosphonates & TDF->TAF switch in HIV+ adults with low BMD. Annual Conference on Retroviruses and Opportunistic Infections (CROI) - CROI Foundation 2018; poster presentation: abstract #724.
  • DeJesus E, Haas B, Segal-Maurer S, Ramgopal MN, Mills A, Margot N, Liu YP, Makadzange T, McCallister S. Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment. AIDS Res Hum Retroviruses. 2018 Apr;34(4):337-342. doi: 10.1089/AID.2017.0203. Epub 2018 Mar 20. PubMed 29368537 ↗
  • Goldstein D, Ward D, Brinson C, Crofoot G, et al. Week 96 efficacy and safety of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in older, HIV-Infected virologically-suppressed adults. Annual Meeting of the American Geriatrics Society (AGS) 2017; poster presentation: abstract #A90.
  • Ward D, Thompson M, Goldstein D, Brinson C, et al. Week 96 efficacy and safety of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in older, HIV-infected treatment-naïve adults. Annual Meeting of the American Geriatrics Society (AGS) 2017; poster presentation: abstract #A91.
  • Choe S, Podzamvzer D, Tashima K, McNicholl I, and McCallister S. Utilizing phase 3 clinical trial data to assess adverse event (AE) frequency of a potentially interacting medication (PIM) amlodipine with elvitegravir/cobicistat (EVG/COBI). Midyear Clinical Meeting of the American Society of Health-System Pharmacists (ASHP) 2017; poster presentation: abstract #7-068.
  • Yin M, Gupta S, Nguyen-Cleary T, Mora M, and Das M. Switching from TDF to TAF in HIV-infected adults with low BMD: A pooled analysis. Congress on HIV and Hepatitis in the Americas - ViiV Healthcare UK Limited 2017; poster presentation: abstract #P021.
  • Podzamczer D, Tashima K, Daar E, McGowan J, et al. Utilizing phase 3 clinical trial data to assess adverse event (AE) frequency of a potentially interacting medication (PIM) amlodipine with elvitegravir/cobicistat (EVG/COBI). International Congress of Drug Therapy in HIV Infection - International AIDS Society 2016; poster presentation: abstract #P314.
  • Dejesus E, Haas B, Segal-Maurer S, Ramgopal M, et al. Superior efficacy and improved renal and bone safety after switching from a tenofovir disoproxil fumarate (TDF) regimen to a tenofovir alafenamide (TAF) based regimen through 96 weeks (W96) of treatment. 56th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held Jointly with the 2016 Annual Meeting on Microbe - American Society for Microbiology (ASM) 2016; poster presentation: abstract # LB-087.
  • Viciana P, Rijnders B, Shalit P, Liu Y et al. Cambio desde TDF a TAF en pacientes en alto riesgo de erc. 18th Congress of the Andalusian Society of Infectious Diseases (SAID) 2016; poster presentation: abstract #P-070.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2013 to primary completion in Mar 2015, 23 months.

Results were first posted in Apr 2016, 1 year after primary completion. A results delay was requested in Oct 2014.

Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 23 months is close to that.

Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2013
First posted
Mar 21, 2013
StartActual
Mar 27, 2013
Primary completionActual
Mar 16, 2015
CompletionActual
Apr 1, 2020
Results delay requested
Oct 30, 2014
Results first posted
Apr 14, 2016
Last update
Apr 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01815736
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Mar 21, 2013
Start date
Mar 27, 2013
Primary completion
Mar 16, 2015
Completion
Apr 1, 2020
Results posted
Apr 14, 2016
Last update
Apr 13, 2021

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide

Start the discussion